Drug repositioning based on individual bi-random walks on a heterogeneous network
Background Traditional drug research and development is high cost, time-consuming and risky. Computationally identifying new indications for existing drugs, referred as drug repositioning, greatly reduces the cost and attracts ever-increasing research interests. Many network-based methods have been proposed for drug repositioning and most of them apply random walk on a heterogeneous network consisted with disease and drug nodes. However, these methods generally adopt the same walk-length for all nodes, and ignore the different contributions of different nodes. Results In this study, we propose a drug repositioning approach based on individual bi-random walks (DR-IBRW) on the heterogeneous network. DR-IBRW firstly quantifies the individual work-length of random walks for each node based on the network topology and knowledge that similar drugs tend to be associated with similar diseases. To account for the inner structural difference of the heterogeneous network, it performs bi-random walks with the quantified walk-lengths, and thus to identify new indications for approved drugs. Empirical study on public datasets shows that DR-IBRW achieves a much better drug repositioning performance than other related competitive methods. Conclusions Using individual random walk-lengths for different nodes of heterogeneous network indeed boosts the repositioning performance. DR-IBRW can be easily generalized to prioritize links between nodes of a network..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
BMC bioinformatics - 20(2019), Suppl 15 vom: 24. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yuehui [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Bi-random walks |
|---|
| Anmerkungen: |
© The Author(s) 2019 |
|---|
| doi: |
10.1186/s12859-019-3117-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR026927462 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR026927462 | ||
| 003 | DE-627 | ||
| 005 | 20230519081259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12859-019-3117-6 |2 doi | |
| 035 | |a (DE-627)SPR026927462 | ||
| 035 | |a (SPR)s12859-019-3117-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yuehui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug repositioning based on individual bi-random walks on a heterogeneous network |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2019 | ||
| 520 | |a Background Traditional drug research and development is high cost, time-consuming and risky. Computationally identifying new indications for existing drugs, referred as drug repositioning, greatly reduces the cost and attracts ever-increasing research interests. Many network-based methods have been proposed for drug repositioning and most of them apply random walk on a heterogeneous network consisted with disease and drug nodes. However, these methods generally adopt the same walk-length for all nodes, and ignore the different contributions of different nodes. Results In this study, we propose a drug repositioning approach based on individual bi-random walks (DR-IBRW) on the heterogeneous network. DR-IBRW firstly quantifies the individual work-length of random walks for each node based on the network topology and knowledge that similar drugs tend to be associated with similar diseases. To account for the inner structural difference of the heterogeneous network, it performs bi-random walks with the quantified walk-lengths, and thus to identify new indications for approved drugs. Empirical study on public datasets shows that DR-IBRW achieves a much better drug repositioning performance than other related competitive methods. Conclusions Using individual random walk-lengths for different nodes of heterogeneous network indeed boosts the repositioning performance. DR-IBRW can be easily generalized to prioritize links between nodes of a network. | ||
| 650 | 4 | |a Drug repositioning |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug-disease heterogeneous network |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Individual walk-length |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bi-random walks |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Guo, Maozu |4 aut | |
| 700 | 1 | |a Ren, Yazhou |4 aut | |
| 700 | 1 | |a Jia, Lianyin |4 aut | |
| 700 | 1 | |a Yu, Guoxian |0 (orcid)0000-0002-1667-6705 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC bioinformatics |d London : BioMed Central, 2000 |g 20(2019), Suppl 15 vom: 24. Dez. |w (DE-627)SPR02681952X |w (DE-600)2041484-5 |x 1471-2105 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2019 |g number:Suppl 15 |g day:24 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12859-019-3117-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2019 |e Suppl 15 |b 24 |c 12 | ||